Imexpharm Corp (IMP) - Net Assets
Based on the latest financial reports, Imexpharm Corp (IMP) has net assets worth ₫2.31 Trillion VND (≈ $87.63 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₫2.78 Trillion ≈ $105.72 Million USD) and total liabilities (₫476.11 Billion ≈ $18.09 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Imexpharm Corp liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₫2.31 Trillion |
| % of Total Assets | 82.89% |
| Annual Growth Rate | 6.75% |
| 5-Year Change | 28.54% |
| 10-Year Change | N/A |
| Growth Volatility | 2.74 |
Imexpharm Corp - Net Assets Trend (2019–2025)
This chart illustrates how Imexpharm Corp's net assets have evolved over time, based on quarterly financial data. Also explore IMP asset base for the complete picture of this company's asset base.
Annual Net Assets for Imexpharm Corp (2019–2025)
The table below shows the annual net assets of Imexpharm Corp from 2019 to 2025. For live valuation and market cap data, see IMP market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₫2.31 Trillion ≈ $87.63 Million |
+5.65% |
| 2024-12-31 | ₫2.18 Trillion ≈ $82.95 Million |
+4.73% |
| 2023-12-31 | ₫2.08 Trillion ≈ $79.20 Million |
+10.04% |
| 2022-12-31 | ₫1.89 Trillion ≈ $71.98 Million |
+5.57% |
| 2021-12-31 | ₫1.79 Trillion ≈ $68.18 Million |
+3.69% |
| 2020-12-31 | ₫1.73 Trillion ≈ $65.75 Million |
+11.01% |
| 2019-12-31 | ₫1.56 Trillion ≈ $59.23 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Imexpharm Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₫449.01 Billion | 19.47% |
| Other Components | ₫1.86 Trillion | 80.53% |
| Total Equity | ₫2.31 Trillion | 100.00% |
Imexpharm Corp Competitors by Market Cap
The table below lists competitors of Imexpharm Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
QST International
TWO:8349
|
$297.37 Million |
|
Kizilbuk Gayrimenkul Yatirim Ortakligi AS
IS:KZBGY
|
$297.44 Million |
|
NEXCOM International Co Ltd
TWO:8234
|
$297.67 Million |
|
NRB Bearing Limited
NSE:NRBBEARING
|
$297.70 Million |
|
Castro
TA:CAST
|
$297.24 Million |
|
29METALS Ltd
AU:29M
|
$297.19 Million |
|
TRANSILVANIA INVESTMENTS ALLIANCE S.A.
RO:TRANSI
|
$297.17 Million |
|
Cerro de Pasco Resources Inc.
V:CDPR
|
$296.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Imexpharm Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,183,119,168,600 to 2,306,522,178,891, a change of 123,403,010,291 (5.7%).
- Net income of 349,138,023,396 contributed positively to equity growth.
- Dividend payments of 77,004,481,000 reduced retained earnings.
- Other factors decreased equity by 148,730,532,105.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₫349.14 Billion | +15.14% |
| Dividends Paid | ₫77.00 Billion | -3.34% |
| Other Changes | ₫-148.73 Billion | -6.45% |
| Total Change | ₫- | 5.65% |
Book Value vs Market Value Analysis
This analysis compares Imexpharm Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.39x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.12x to 3.39x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | ₫23912.53 | ₫50800.00 | x |
| 2020-12-31 | ₫25955.38 | ₫50800.00 | x |
| 2021-12-31 | ₫26914.17 | ₫50800.00 | x |
| 2022-12-31 | ₫28414.61 | ₫50800.00 | x |
| 2023-12-31 | ₫29777.72 | ₫50800.00 | x |
| 2024-12-31 | ₫14175.27 | ₫50800.00 | x |
| 2025-12-31 | ₫14976.55 | ₫50800.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Imexpharm Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.14%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.30%
- • Asset Turnover: 0.88x
- • Equity Multiplier: 1.21x
- Recent ROE (15.14%) is above the historical average (12.73%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 10.42% | 11.58% | 0.76x | 1.18x | ₫6.50 Billion |
| 2020 | 12.12% | 15.31% | 0.65x | 1.21x | ₫36.65 Billion |
| 2021 | 10.54% | 14.93% | 0.55x | 1.28x | ₫9.65 Billion |
| 2022 | 11.80% | 13.60% | 0.72x | 1.20x | ₫34.10 Billion |
| 2023 | 14.37% | 15.02% | 0.83x | 1.15x | ₫91.10 Billion |
| 2024 | 14.70% | 14.55% | 0.88x | 1.15x | ₫102.55 Billion |
| 2025 | 15.14% | 14.30% | 0.88x | 1.21x | ₫118.49 Billion |
Industry Comparison
This section compares Imexpharm Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,873,401,354,350
- Average return on equity (ROE) among peers: 16.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Imexpharm Corp (IMP) | ₫2.31 Trillion | 10.42% | 0.21x | $297.25 Million |
| Binh Dinh Pharmaceutical and Medical Equipment JSC (DBD) | $1.14 Trillion | 16.58% | 0.37x | $179.14 Million |
| DHG Pharmaceutical JSC (DHG) | $3.57 Trillion | 20.74% | 0.25x | $496.76 Million |
| DOMESCO Medical Import Export JSC (DMC) | $1.61 Trillion | 12.57% | 0.14x | $76.53 Million |
| Traphaco JSC (TRA) | $1.17 Trillion | 16.70% | 0.41x | $121.26 Million |
About Imexpharm Corp
Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company's products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and mine… Read more